Biological Trace Element Research

, Volume 155, Issue 2, pp 295–300 | Cite as

Bis(oxalato)dioxovanadate(V) and Bis(oxalato)oxoperoxo-vanadate(V) Complexes: Spectroscopic Characterization and Biological Activity

  • Ignacio E. León
  • Susana B. Etcheverry
  • Beatriz S. Parajón-Costa
  • Enrique J. BaranEmail author


Two structurally related vanadium(V) complexes, K3[VO2(C2O4)2]·3H2O and K3[VO(O2)(C2O4)2]·1/2H2O, were thoroughly characterized by infrared, Raman, and electronic spectroscopies. The effect of both complexes on the viability of the human MG-63 osteosarcoma cells was tested using the MTT assay. The monoperoxo complex shows a very strong antiproliferative activity (at 100-μM concentration, this complex diminished the cell viability ca. 80 %), whereas the dioxo complex was inactive.


Vanadium(V) Bis(oxalato) complexes Peroxo ligand Vibrational spectra Electronic spectra Osteosarcoma cells in culture 



This work was supported by the Agencia Nacional de Promoción Cientifica y Tecnológica-ANPCyT (PICT 2218), by the Consejo Nacional de Investigaciones Científicas y Técnicas-CONICET (PIP 1125), and by the Universidad Nacional de La Plata (X-560 and X-554). IEL is a fellow from ANPCyT, and SBE and BSPC are members of the Research Career from CONICET.


  1. 1.
    Rehder D (2008) Bioinorganic vanadium chemistry. Wiley, ChichesterCrossRefGoogle Scholar
  2. 2.
    Barrio DA, Etcheverry SB (2010) Potential use of vanadium compounds in therapeutics. Curr Med Chem 17:3632–3642PubMedCrossRefGoogle Scholar
  3. 3.
    Rehder D (2012) The potentiality of vanadium in medicinal applications. Future Med Chem 4:1823–1837PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson KH, McNeill JH, Orvig C (1999) Vanadium-containing insulin drugs. In: Clarke MJ, Sadler PJ (eds) Metallopharmaceuticals II. Springer, Berlin, pp 139–158CrossRefGoogle Scholar
  5. 5.
    Thompson KH, Orvig C (2006) Vanadium in diabetes: 100 years from phase 0 to phase I. J Inorg Biochem 100:1925–1935PubMedCrossRefGoogle Scholar
  6. 6.
    Levina A, Lay PA (2011) Metal-based anti-diabetic drugs: advances and challenges. Dalton Trans 40:11675–11686PubMedCrossRefGoogle Scholar
  7. 7.
    Barrio DA, Costa-Pessoa J, Etcheverry SB (2012) Diabetes mellitus y vanadio. In: Gambino D, Moreno V, Navarro M (eds) Aplicaciones de los compuestos metálicos en medicina. EAE-LAP Lambert Academic Publishing GmbH & Co KG, Saarbrücken, pp 227–322Google Scholar
  8. 8.
    Evangelou AM (2002) Vanadium in cancer treatment. Crit Rev Oncol Hematol 42:249–265PubMedCrossRefGoogle Scholar
  9. 9.
    Djordjevic C (1995) Antitumor activity of vanadium compounds. In: Sigel H, Sigel A (eds) Metal ions in biological systems, vol. 31: vanadium and its role in life. Marcel Dekker, New York, pp 595–616Google Scholar
  10. 10.
    D’Cruz OJ, Uckun FM (2002) Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin Invest Drugs 11:1829–1836CrossRefGoogle Scholar
  11. 11.
    Benítez J, Guggeri L, Tomaz I, Arrambide G, Navarro M, Costa Pessoa J, Garat B, Gambino D (2009) Design of vanadium mixed-ligand complexes as potential anti-protozoa agents. J Inorg Biochem 103:609–616PubMedCrossRefGoogle Scholar
  12. 12.
    Benítez J, Guggeri L, Tomaz L, Costa Pessoa J, Moreno V, Lorenzo J, Avilés FX, Garat B, Gambino D (2009) A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: a potential anti-protozoa and anti-tumor agent. J Inorg Biochem 103:1386–1394PubMedCrossRefGoogle Scholar
  13. 13.
    Maiti A, Ghosh S (1989) Synthesis and reactivity of the oxovanadium(IV) complexes of two NO donors and potentiation of the antituberculosis activity of them on chelation to metal ions. Part IV. J Inorg Biochem 36:131–139PubMedCrossRefGoogle Scholar
  14. 14.
    Baran EJ (2003) Model studies related to vanadium biochemistry: recent advances and perspectives. J Braz Chem Soc 14:878–888CrossRefGoogle Scholar
  15. 15.
    Baran EJ (2008) Vanadium detoxification: chemical and biochemical aspects. Chem Biodivers 5:1475–1484PubMedCrossRefGoogle Scholar
  16. 16.
    Nielsen FH (1995) Vanadium in mammalian physiology and nutrition. In: Sigel H, Sigel A (eds) Metal ions in biological systems, vol. 31: vanadium and its role in life. Marcel Dekker, New York, pp 543–573Google Scholar
  17. 17.
    Stomberg R (1986) The crystal structures of potassium bis(oxalate)oxoperoxovanadate(V) hemihydrate, K3[VO(O2)(C2O4)2].1/2H2O, and potassium bis(oxalato)dioxovanadate(V) trihydrate, K3[VO2(C2O4)2].3H2O. Acta Chem Scand A40:166–178Google Scholar
  18. 18.
    Schwendt P, Petrovič P (1980) Oxo-peroxo Komplexe des Vanadiums(V). Z Anorg Allg Chem 466:232–236CrossRefGoogle Scholar
  19. 19.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65:55–63CrossRefGoogle Scholar
  20. 20.
    Tatiersky J, Pacigová S, Sivák M, Schwendt P (2009) Monoperoxidovanadium(V) complexes: synthesis, structure and solution properties. J Argent Chem Soc 97:181–198Google Scholar
  21. 21.
    Drew FW, Einstein FWB, Gransden SE (1974) The crystal structure of tripotassium bis(oxalate)dioxovanadate(V) trihydrate. Can J Chem 52:2184–2189CrossRefGoogle Scholar
  22. 22.
    Siebert H (1966) Anwendungen der Schwingungsspektroskopie in der Anorganischen Chemie. Springer, BerlinCrossRefGoogle Scholar
  23. 23.
    Libowitzky E (1990) Correlation of O-H stretching frequencies and O-HO hydrogen bond lengths in minerals. Monatsh Chem 130:1047–1059CrossRefGoogle Scholar
  24. 24.
    Taguchi K, Isobe K, Nakamura Y, Kawaguchi S (1978) Cis-dioxo vanadium(V) and mixed-valence divanadium(IV, V) complexes containing β-diketonate and hetrocyclic nitrogen-base ligands. Bull Chem Soc Jpn 51:2030–2035CrossRefGoogle Scholar
  25. 25.
    D’Antonio MC, Mancilla N, Wladimirsky A, Palacios D, González-Baró AC, Baran EJ (2010) Vibrational spectra of magnesium oxalates. Vibrat Spectrosc 53:218–221CrossRefGoogle Scholar
  26. 26.
    Wladimirsky A, Palacios D, D’Antonio MC, González-Baró AC, Baran EJ (2011) Vibrational spectra of the α-MIIC2O4·2H2O oxalato complexes, with MII = Co, Ni, Zn. J Argent Chem Soc 98:71–77Google Scholar
  27. 27.
    Hind AR, Bhargava SK, van Bronswijk W, Grocott SC, Eyer SL (1998) On the aqueous vibrational spectra of alkali metal oxalates. Appl Spectr 52:683–691CrossRefGoogle Scholar
  28. 28.
    Ross SD (1972) Inorganic infrared and Raman spectra. McGraw-Hill, LondonGoogle Scholar
  29. 29.
    Müller A, Baran EJ, Carter RO (1976) Vibrational spectra of oxo-, thio-, and selenometallates of transition elements in the solid state. Struct Bond 26:81–139CrossRefGoogle Scholar
  30. 30.
    Griffith WP (1964) Studies on transition-metal peroxy-complexes.III. Peroxy-complexes of groups IVA, VA and VIA. J Chem Soc 5248–5253Google Scholar
  31. 31.
    Müller A, Diemann E, Jorgensen CK (1973) Electronic spectra of tetrahedral oxo-, thio and seleno complexes formed by elements of the beginning of the transition groups. Struct Bond 14:23–47CrossRefGoogle Scholar
  32. 32.
    Bishayee A, Wagharay A, Patel MA, Chatterjee M (2010) Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett 294:1–12PubMedCrossRefGoogle Scholar
  33. 33.
    Djordjevic C, Wampler GL (1985) Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J Inorg Biochem 28:51–55CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ignacio E. León
    • 1
    • 2
  • Susana B. Etcheverry
    • 1
    • 2
  • Beatriz S. Parajón-Costa
    • 2
  • Enrique J. Baran
    • 2
    Email author
  1. 1.Cátedra de Bioquímica Patológica, Facultad de Ciencias ExactasUniversidad Nacional de La PlataLa PlataArgentina
  2. 2.Centro de Química Inorgánica (CEQUINOR/CONICET,UNLP), Facultad de Ciencias ExactasUniversidad Nacional de La PlataLa PlataArgentina

Personalised recommendations